{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:01:59Z","timestamp":1791838919183,"version":"4.3.4"},"reference-count":139,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Alopecia areata (AA) is a non-scarring inflammatory hair loss disorder characterized by a T-cell\u2013mediated autoimmune disease that targets the hair follicles. In particular, Natural Killer Group 2 member D (NKG2D)\n                    <jats:sup>+<\/jats:sup>\n                    CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells have been identified as central players in its pathogenesis. Current treatment options have limited efficacy and are often associated with adverse effects and high risk of relapse upon discontinuation, highlighting the need for targeted and durable therapeutic strategies. Janus kinase (JAK) inhibitors have emerged as representative therapies; however, they are limited by a high relapse rate after treatment cessation. Recently, novel therapeutic approaches such as neutralizing antibodies targeting cytokines and chemokines, and sphingosine-1-phosphate (S1P) receptor modulators have gained attention. Various molecular markers associated with AA have been identified as potential therapeutic targets. This review provides a comprehensive overview of the roles of immune cells in AA pathogenesis and introduces emerging immunomodulatory strategies and novel therapeutic targets.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1681163","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:23:59Z","timestamp":1762496639000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Alopecia areata: from immunopathogenesis to emerging therapeutic approaches"],"prefix":"10.3389","volume":"16","author":[{"given":"Su-Young","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Joo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihye","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beom Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon","family":"Seok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1177\/12034754231168839","article-title":"Alopecia areata: an updated review for 2023","volume":"27","author":"Sibbald","year":"2023","journal-title":"J Cutan Med Surg"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","article-title":"Alopecia areata","volume":"3","author":"Pratt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12209","article-title":"What causes alopecia areata","volume":"22","author":"McElwee","year":"2013","journal-title":"Exp Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5701183","article-title":"Maintenance of hair follicle immune privilege is linked to prevention of Nk cell attack","volume":"128","author":"Ito","year":"2008","journal-title":"J Invest Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.3390\/cells10123397","article-title":"The role of serum Th1, Th2, and Th17 cytokines in patients with alopecia areata: clinical implications","volume":"10","author":"Waskiel-Burnat","year":"2021","journal-title":"Cells"},{"key":"B6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jdermsci.2021.10.006","article-title":"Pathological functions of granzyme B in inflammatory skin diseases","volume":"104","author":"Hiroyasu","year":"2021","journal-title":"J Dermatol Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.3390\/ijms25115652","article-title":"Deciphering the complex immunopathogenesis of alopecia areata","volume":"25","author":"Sutic Udovic","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2018.77608","article-title":"Efficacy of diphenylcyclopropenone in alopecia areata: A comparison of two treatment regimens","volume":"35","author":"Nowicka","year":"2018","journal-title":"Postepy Dermatol Alergol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01421-2","article-title":"Local corticosteroids for alopecia areata: A narrative review","volume":"15","author":"Gregoire","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jaad.2018.06.064","article-title":"Methotrexate for alopecia areata: A systematic review and meta-analysis","volume":"80","author":"Phan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1886230","article-title":"Efficacy and predictive factors of cyclosporine a in alopecia areata: A systematic review with meta-analysis","volume":"33","author":"Husein-ElAhmed","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/phpp.12596","article-title":"Excimer laser\/light treatment of alopecia areata: A systematic review and meta-analyses","volume":"36","author":"Lee","year":"2020","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.955035","article-title":"An overview of Jak\/Stat pathways and Jak inhibition in alopecia areata","volume":"13","author":"Lensing","year":"2022","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.3390\/genes1030413","article-title":"Lifestyle factors involved in the pathogenesis of alopecia areata","volume":"23","author":"Minokawa","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08883-0","article-title":"Alopecia areata: an update on etiopathogenesis, diagnosis, and management","volume":"61","author":"Zhou","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jdermsci.2015.01.004","article-title":"The genetics of alopecia areata: new approaches, new findings, new treatments","volume":"78","author":"Biran","year":"2015","journal-title":"J Dermatol Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.crimmu.2021.02.001","article-title":"Immunopathogenesis of alopecia areata","volume":"2","author":"Olayinka","year":"2021","journal-title":"Curr Res Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","article-title":"T cells in health and disease","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01105-x","article-title":"Cd8 T-cell subsets: heterogeneity, functions, and therapeutic potential","volume":"55","author":"Koh","year":"2023","journal-title":"Exp Mol Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by Jak inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/1346-8138.17064","article-title":"Alopecia areata: what\u2019s new in the diagnosis and treatment with Jak inhibitors","volume":"51","author":"Dainichi","year":"2024","journal-title":"J Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01547-5","article-title":"A virtual memory Cd8(+) T cell-originated subset causes alopecia areata through innate-like cytotoxicity","volume":"24","author":"Seok","year":"2023","journal-title":"Nat Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd1866","article-title":"Blockade of Il-7 signaling suppresses inflammatory responses and reverses alopecia areata in C3h\/Hej mice","volume":"7","author":"Dai","year":"2021","journal-title":"Sci Adv"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.121949","article-title":"High-throughput T cell receptor sequencing identifies clonally expanded Cd8+ T cell populations in alopecia areata","volume":"3","author":"de Jong","year":"2018","journal-title":"JCI Insight"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115798","article-title":"Single-cell analysis of temporal immune cell dynamics in alopecia areata reveals a causal role for clonally expanded Cd8(+) T cells in disease","volume":"44","author":"Dai","year":"2025","journal-title":"Cell Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1046\/j.1087-0024.2003.00805.x","article-title":"Characterization of hair follicle antigens targeted by the anti-hair follicle immune response","volume":"8","author":"Tobin","year":"2003","journal-title":"J Invest Dermatol Symposium Proc"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.12.005","article-title":"Melanocytes: A possible autoimmune target in alopecia areata","volume":"61","author":"Trautman","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1021\/pr100422u","article-title":"Trichohyalin is a potential major autoantigen in human alopecia areata","volume":"9","author":"Leung","year":"2010","journal-title":"J Proteome Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.890027","article-title":"Autoantigen discovery in the hair loss disorder, alopecia areata: implication of post-translational modifications","volume":"13","author":"Jadeja","year":"2022","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nri3152","article-title":"Expanding roles for Cd4(+) T cells in immunity to viruses","volume":"12","author":"Swain","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23692.x","article-title":"Transfer of Cd8(+) cells induces localized hair loss whereas Cd4(+)\/Cd25(-) cells promote systemic alopecia areata and Cd4(+)\/Cd25(+) cells blockade disease onset in the C3h\/Hej mouse model","volume":"124","author":"McElwee","year":"2005","journal-title":"J Invest Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12978","article-title":"Imbalance of T-helper 17 and regulatory T cells in patients with alopecia areata","volume":"42","author":"Han","year":"2015","journal-title":"J Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14775","article-title":"Role of T helper 17 cells and T regulatory cells in alopecia areata: comparison of lesion and serum cytokine between controls and patients","volume":"32","author":"Loh","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12396","article-title":"T-helper and regulatory T-cell cytokines in the peripheral blood of patients with active alopecia areata","volume":"169","author":"Tembhre","year":"2013","journal-title":"Br J Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210308","article-title":"Alopecia areata patients show deficiency of Foxp3+Cd39+ T regulatory cells and clonotypic restriction of Treg Tcrbeta-chain, which highlights the immunopathological aspect of the disease","volume":"14","author":"Hamed","year":"2019","journal-title":"PloS One"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-012-0224-3","article-title":"Single nucleotide polymorphisms in the promoter regions of Foxp3 and Icoslg genes are associated with alopecia areata","volume":"14","author":"Conteduca","year":"2014","journal-title":"Clin Exp Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nature09114","article-title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity","volume":"466","author":"Petukhova","year":"2010","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2013.01.006","article-title":"Impaired inhibitory function of circulating Cd4+Cd25+ Regulatory T cells in alopecia areata","volume":"70","author":"Shin","year":"2013","journal-title":"J Dermatol Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2305764120","article-title":"Functional interrogation of lymphocyte subsets in alopecia areata using single-cell Rna sequencing","volume":"120","author":"Lee","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nri1199","article-title":"Roles of the Nkg2d immunoreceptor and its ligands","volume":"3","author":"Raulet","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2020.09.001","article-title":"Pro-inflammatory vdelta1(+)T-cells infiltrates are present in and around the hair bulbs of non-lesional and lesional alopecia areata hair follicles","volume":"100","author":"Uchida","year":"2020","journal-title":"J Dermatol Sci"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cytogfr.2007.10.006","article-title":"Plasmacytoid dendritic cells and type I Ifn: 50 years of convergent history","volume":"19","author":"Fitzgerald-Bocarsly","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"key":"B43","doi-asserted-by":"publisher","first-page":"87","DOI":"10.5021\/ad.2019.31.1.87","article-title":"Plasmacytoid dendritic cells in pityriasis rubra pilaris","volume":"31","author":"Al-Hage","year":"2019","journal-title":"Ann Dermatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s13238-012-2104-8","article-title":"Regulation of Tlr7\/9 signaling in plasmacytoid dendritic cells","volume":"4","author":"Bao","year":"2013","journal-title":"Protein Cell"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12932","article-title":"Plasmacytoid dendritic cells in alopecia areata: missing link","volume":"30","author":"Abou Rahal","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2019.07.009","article-title":"Plasmacytoid dendritic cells as a possible key player to initiate alopecia areata in the C3h\/Hej mouse","volume":"69","author":"Ito","year":"2020","journal-title":"Allergol Int"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03770.x","article-title":"Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor-alpha blocker agents: report of five cases and review of the literature","volume":"25","author":"Ferran","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000162180","article-title":"Alopecia areata universalis during treatment of rheumatoid arthritis with anti-Tnf-alpha antibody (Adalimumab)","volume":"217","author":"Chaves","year":"2008","journal-title":"Dermatology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.6.759","article-title":"Recurrence of alopecia areata in a patient receiving etanercept injections","volume":"141","author":"Posten","year":"2005","journal-title":"Arch Dermatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0408506102","article-title":"Cross-regulation of Tnf and Ifn-alpha in autoimmune diseases","volume":"102","author":"Palucka","year":"2005","journal-title":"Natl Acad Sci United States America"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-015-1539-1","article-title":"Lesional infiltration of mast cells, langerhans cells, T cells and local cytokine profiles in alopecia areata","volume":"307","author":"Zhang","year":"2015","journal-title":"Arch Dermatol Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094260","article-title":"Abnormal interactions between perifollicular mast cells and Cd8+ T-cells may contribute to the pathogenesis of alopecia areata","volume":"9","author":"Bertolini","year":"2014","journal-title":"PloS One"},{"key":"B53","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jdermsci.2013.04.029","article-title":"Antihistaminic drug olopatadine downmodulates T cell chemotaxis toward Cxcl10 by reducing Cxcr3 expression, F-actin polymerization and calcium influx in patients with alopecia areata","volume":"72","author":"Ito","year":"2013","journal-title":"J Dermatol Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2010.03.009","article-title":"Experimental evaluation of ebastine, a second-generation anti-histamine, as a supportive medication for alopecia areata","volume":"58","author":"Ohyama","year":"2010","journal-title":"J Dermatol Sci"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2020.10.001","article-title":"Type 1 innate lymphoid cells: soldiers at the front line of immunity","volume":"44","author":"Nabekura","year":"2021","journal-title":"BioMed J"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.002","article-title":"Cancer immunosurveillance by tissue-resident innate lymphoid cells and innate-like T cells","volume":"164","author":"Dadi","year":"2016","journal-title":"Cell"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01219","article-title":"The role of natural killer group 2, member D in chronic inflammation and autoimmunity","volume":"9","author":"Babic","year":"2018","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00661","article-title":"Nkg2d\/Nkg2-ligand pathway offers new opportunities in cancer treatment","volume":"10","author":"Frazao","year":"2019","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.80768","article-title":"Involvement of Ilc1-like innate lymphocytes in human autoimmunity, lessons from alopecia areata","volume":"12","author":"Laufer Britva","year":"2023","journal-title":"Elife"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1372009","article-title":"Balancing immune responses: regulatory cells in eosinophilic gastrointestinal disorders","volume":"15","author":"Kheshtchin","year":"2024","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0314600","article-title":"Hematological ratios as an indicator of severity in alopecia areata: A retrospective nationwide study","volume":"19","author":"Andre","year":"2024","journal-title":"PLoS One"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)70219-6","article-title":"Eosinophils in fibrous tracts and near hair bulbs: A helpful diagnostic feature of alopecia areata","volume":"37","author":"Elston","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.02.017","article-title":"Histologic features of alopecia areata other than peribulbar lymphocytic infiltrates","volume":"65","author":"Peckham","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(00)90152-x","article-title":"Eosinophils in fibrous tracts and near hair bulbs: A helpful diagnostic feature of alopecia areata","volume":"42","author":"El Darouti","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.62","article-title":"Diagnostic usefulness of a peribulbar eosinophilic infiltrate in alopecia areata","volume":"150","author":"Yoon","year":"2014","journal-title":"JAMA Dermatol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1176724","article-title":"Towards a better understanding of human Inkt cell subpopulations for improved clinical outcomes","volume":"14","author":"Look","year":"2023","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jaut.2018.04.001","article-title":"Inkt cells ameliorate human autoimmunity: lessons from alopecia areata","volume":"91","author":"Ghraieb","year":"2018","journal-title":"J Autoimmun"},{"key":"B68","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.revmed.2024.10.452","article-title":"Jak inhibitors (Jaki): mechanisms of action and perspectives in systemic and autoimmune diseases","volume":"46","author":"Chikhoune","year":"2025","journal-title":"Rev Med Interne"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1500973","article-title":"Pharmacologic inhibition of Jak-Stat signaling promotes hair growth","volume":"1","author":"Harel","year":"2015","journal-title":"Sci Adv"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00764-w","article-title":"Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase iii trials (Brave-aa1 and Brave-aa2)","volume":"24","author":"Kwon","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19665","article-title":"Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from Brave-aa1 and Brave-aa2","volume":"38","author":"Senna","year":"2024","journal-title":"J Eur Acad Dermatol Venereology: JEADV"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.06.097","article-title":"Efficacy and safety of deuruxolitinib, an oral selective janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (Thrive-aa1)","volume":"91","author":"King","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"key":"B75","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0092-8674(00)81168-X","article-title":"Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis","volume":"93","author":"Neubauer","year":"1998","journal-title":"Cell"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.14220","article-title":"Selective inhibition of jak3 signaling is sufficient to reverse alopecia areata","volume":"6","author":"Dai","year":"2021","journal-title":"JCI Insight"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.955038","article-title":"Induction of T cell exhaustion by Jak1\/3 inhibition in the treatment of alopecia areata","volume":"13","author":"Dai","year":"2022","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.4.2059","article-title":"Cutting edge: an alternative pathway of Cd4+ T cell differentiation is induced following activation in the absence of gamma-chain-dependent cytokine signals","volume":"176","author":"Mayack","year":"2006","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: A randomised, double-blind, multicentre, phase 2b-3 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20526","article-title":"Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% Scalp hair loss: results from the allegro-lt phase 3, open-label study","volume":"39","author":"Tziotzios","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20547","article-title":"Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the allegro clinical development programme","volume":"39","author":"King","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1372810","article-title":"Comparative efficacy and safety of Jak inhibitors in the treatment of moderate-to-severe alopecia areata: A systematic review and network meta-analysis","volume":"15","author":"Yan","year":"2024","journal-title":"Front Pharmacol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.70185","article-title":"The relative efficacy and safety of monotherapies for alopecia areata: A network meta-analysis study","volume":"24","author":"Gupta","year":"2025","journal-title":"J Cosmet Dermatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20372","article-title":"Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata","volume":"39","author":"Aceituno","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1577115","article-title":"Janus kinase inhibitors for alopecia areata: A review of clinical data","volume":"16","author":"Sun","year":"2025","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1243556","article-title":"Inhibition of T-cell activity in alopecia areata: recent developments and new directions","volume":"14","author":"Passeron","year":"2023","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.02.083","article-title":"Clinical response and safety of upadacitinib for alopecia areata: A retrospective study","volume":"93","author":"Li","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.2734","article-title":"Baricitinib withdrawal and retreatment in patients with severe alopecia areata: the brave-aa1 randomized clinical trial","volume":"160","author":"King","year":"2024","journal-title":"JAMA Dermatol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.648408","article-title":"Low-dose Il-2 therapy in autoimmune and rheumatic diseases","volume":"12","author":"Grasshoff","year":"2021","journal-title":"Front Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1111547","article-title":"The potential of regulatory T cell-based therapies for alopecia areata","volume":"14","author":"Wan","year":"2023","journal-title":"Front Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.504","article-title":"Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata","volume":"150","author":"Castela","year":"2014","journal-title":"JAMA Dermatol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jid.2020.08.015","article-title":"Low-dose Il-2 for treating moderate to severe alopecia areata: A 52-week multicenter prospective placebo-controlled study assessing its impact on T regulatory cell and Nk cell populations","volume":"141","author":"Le Duff","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.874778","article-title":"Selective expansion of Tregs using the Il-2 cytokine antibody complex does not reverse established alopecia areata in C3h\/Hej mice","volume":"13","author":"Lee","year":"2022","journal-title":"Front Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70182","article-title":"Alopecia areata: pathogenesis, diagnosis, and therapies","volume":"6","author":"Ma","year":"2025","journal-title":"MedComm (2020)"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.3390\/ijms25031705","article-title":"Cxcl12 neutralizing antibody promotes hair growth in androgenic alopecia and alopecia areata","volume":"25","author":"Zheng","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14129","article-title":"Understanding the significance of cytokines and chemokines in the pathogenesis of alopecia areata","volume":"29","author":"Ito","year":"2020","journal-title":"Exp Dermatol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4062\/biomolther.2016.160","article-title":"Sphingosine 1-phosphate receptor modulators and drug discovery","volume":"25","author":"Park","year":"2017","journal-title":"Biomol Ther (Seoul)"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00244-0","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions","volume":"398","author":"McGinley","year":"2021","journal-title":"Lancet"},{"key":"B99","volume-title":"Cellular and Molecular Immunology","author":"Abbas","year":"2017"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20605","article-title":"Efficacy and safety of etrasimod in alopecia areata: A multicentre, randomized, double-blind, placebo-controlled, phase 2 study","volume":"39","author":"King","year":"2025","journal-title":"J Eur Acad Dermatol Venereology: JEADV"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.2976","article-title":"Hair regrowth in a patient with long-standing alopecia totalis and atopic dermatitis treated with dupilumab","volume":"154","author":"Penzi","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1111\/all.13346","article-title":"Alopecia areata is characterized by expansion of circulating Th2\/Tc2\/Th22, within the skin-homing and systemic T-cell populations","volume":"73","author":"Czarnowicki","year":"2018","journal-title":"Allergy"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.06.032","article-title":"Alopecia areata profiling shows Th1, Th2, and Il-23 cytokine activation without parallel Th17\/Th22 skewing","volume":"136","author":"Suarez-Farinas","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18008","article-title":"Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity","volume":"182","author":"Bain","year":"2020","journal-title":"Br J Dermatol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.jaci.2018.06.029","article-title":"An integrated model of alopecia areata biomarkers highlights both T(H)1 and T(H)2 upregulation","volume":"142","author":"Song","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.jaip.2020.01.052","article-title":"Alopecia areata is associated with atopic diathesis: results from a population-based study of 51,561 patients","volume":"8","author":"Kridin","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2312245","article-title":"Dupliumab therapy for alopecia areata: A case series and review of the literature","volume":"35","author":"Huang","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"B108","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/all.15071","article-title":"Phase 2a randomized clinical trial of dupilumab (Anti-Il-4ralpha) for alopecia areata patients","volume":"77","author":"Guttman-Yassky","year":"2022","journal-title":"Allergy"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25179236","article-title":"Mesenchymal stem cell therapy in alopecia areata: visual and molecular evidence from a mouse model","volume":"25","author":"Park","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.4067\/S0716-97602012000300008","article-title":"Mesenchymal stem cell treatment for autoimmune diseases: A critical review","volume":"45","author":"Figueroa","year":"2012","journal-title":"Biol Res"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13255","article-title":"Bone marrow-derived mesenchymal stem cells prevent alopecia areata development through the inhibition of nNkg2d expression: A pilot study","volume":"26","author":"Byun","year":"2017","journal-title":"Exp Dermatol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12916-015-0331-6","article-title":"Hair regrowth in alopecia areata patients following stem cell educator therapy","volume":"13","author":"Li","year":"2015","journal-title":"BMC Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.779177","article-title":"Sirt1: A potential therapeutic target in autoimmune diseases","volume":"12","author":"Shen","year":"2021","journal-title":"Front Immunol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jdermsci.2023.05.005","article-title":"Sirt1 downregulation provokes immune-inflammatory responses in hair follicle outer root sheath cells and may contribute to development of alopecia areata","volume":"111","author":"Hao","year":"2023","journal-title":"J Dermatol Sci"},{"key":"B115","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12865-025-00685-9","article-title":"Modulating immune responses in alopecia: therapeutic insights and potential targets of antisense oligonucleotides","volume":"26","author":"Begum","year":"2025","journal-title":"BMC Immunol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"17622","DOI":"10.1038\/s41598-020-74796-1","article-title":"Hair growth promotion by necrostatin-1s","volume":"10","author":"Zheng","year":"2020","journal-title":"Sci Rep"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0071-y","article-title":"Receptor-interacting protein kinase 1 (Ripk1) as a therapeutic target","volume":"19","author":"Mifflin","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3390\/genes1030413","article-title":"The involvement of ripk1 in alopecia areata","volume":"26","author":"Kim","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.11.009","article-title":"Diverse role of Ox40 on T cells as a therapeutic target for skin diseases","volume":"143","author":"Iriki","year":"2023","journal-title":"J Invest Dermatol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.imlet.2006.04.001","article-title":"Functional characterization of Ox40 expressed on human Cd8+ T cells","volume":"106","author":"Fujita","year":"2006","journal-title":"Immunol Lett"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1111\/all.16268","article-title":"Alopecia areata exhibits cutaneous and systemic Ox40 activation across atopic backgrounds","volume":"79","author":"Kim","year":"2024","journal-title":"Allergy"},{"key":"B122","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/all.13308","article-title":"Mucocutaneous inflammation in the ikaros family zinc finger 1-keratin 5-specific transgenic mice","volume":"73","author":"Ueta","year":"2018","journal-title":"Allergy"},{"key":"B123","doi-asserted-by":"publisher","first-page":"e70074","DOI":"10.1111\/exd.70074","article-title":"Ikzf1 and Ikaros overexpression results in alopecia areata-like phenotype in mice","volume":"34","author":"Arakawa","year":"2025","journal-title":"Exp Dermatol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/nri912","article-title":"Emerging roles of ppars in inflammation and immunity","volume":"2","author":"Daynes","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1080\/000155500459240","article-title":"Expression of peroxisome proliferator activated receptors (Ppars) in human hair follicles and ppar alpha involvement in hair growth","volume":"80","author":"Billoni","year":"2000","journal-title":"Acta dermato-venereologica"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.62347\/JDYZ3863","article-title":"Mechanism of pparalpha agonist in alopecia areata","volume":"17","author":"Xuan","year":"2025","journal-title":"Am J Transl Res"},{"key":"B127","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41423-019-0291-4","article-title":"Tissue-resident memory T cells and their biological characteristics in the recurrence of inflammatory skin disorders","volume":"17","author":"Chen","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad303","article-title":"Resident cutaneous memory T cells: A clinical review of their role in chronic inflammatory dermatoses and potential as therapeutic targets","volume":"189","author":"Pham","year":"2023","journal-title":"Br J Dermatol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1639732","article-title":"Targeting the Il-15\/Cd122 signaling pathway: reversing Trm cell-mediated immune memory in vitiligo","volume":"16","author":"Su","year":"2025","journal-title":"Front Immunol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2744","article-title":"The developmental pathway for Cd103(+)Cd8+ Tissue-resident memory T cells of skin","volume":"14","author":"Mackay","year":"2013","journal-title":"Nat Immunol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","article-title":"Cd49a expression defines tissue-resident Cd8(+) T cells poised for cytotoxic function in human skin","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7710","article-title":"Antibody blockade of Il-15 signaling has the potential to durably reverse vitiligo","volume":"10","author":"Richmond","year":"2018","journal-title":"Sci Transl Med"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.10.036","article-title":"Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers","volume":"149","author":"Guttman-Yassky","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2021.09.001","article-title":"Altered T cell subpopulations and serum anti-tyrp2 and tyrosinase antibodies in the acute and chronic phase of alopecia areata in the C3h\/Hej mouse model","volume":"104","author":"Hashimoto","year":"2021","journal-title":"J Dermatol Sci"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10597.x","article-title":"Demonstration of autoantibodies against tyrosine hydroxylase in patients with alopecia areata","volume":"165","author":"Kemp","year":"2011","journal-title":"Br J Dermatol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-202x.2001.01583.x","article-title":"Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc(Scid) mice","volume":"117","author":"Gilhar","year":"2001","journal-title":"J Invest Dermatol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0413196","article-title":"Tolerance induction by hair-specific keratins in murine alopecia areata","volume":"94","author":"Erb","year":"2013","journal-title":"J Leukoc Biol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.T500004-MCP200","article-title":"Profiling of alopecia areata autoantigens based on protein microarray technology","volume":"4","author":"Lueking","year":"2005","journal-title":"Mol Cell Proteomics"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2003.05610.x","article-title":"A natural canine homologue of alopecia areata in humans","volume":"149","author":"Tobin","year":"2003","journal-title":"Br J Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1681163\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:24:00Z","timestamp":1762496640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1681163\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":139,"alternative-id":["10.3389\/fimmu.2025.1681163"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1681163","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"article-number":"1681163"}}